Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part, Open-Label, Randomized, Crossover Study to Evaluate the Bioequivalence of the 70 mg Alendronate/2800 IU Vitamin D3 Final Market Combination Tablet to a 70 mg Alendronate Marketed Tablet, and the Relative Bioavailability of Vitamin D3

NCT00806416 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT00806416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00806416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part, Open-Label, Randomized, Crossover Study to Evaluate the Bioequivalence of the 70 mg Alendronate/2800 IU Vitamin D3 Final Market Combination Tablet to a 70 mg Alendronate Marketed Tablet, and the Relative Bioavailability of Vitamin D3
Lead sponsor
Organon and Co
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2003
Completion date
January 31, 2004
Enrollment
244 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis